Dry Eye Disease Market Size - By Product (Cyclosporine, Topical Corticosteroids, Artificial Tears, Punctal Plugs, Oral Omega Supplements), By Disease Type (Evaporative Dry Eye Syndrome, Aqueous Deficient Dry Eye Syndrome), By Distribution Channel, & Forecast, 2023 – 2032

Dry Eye Disease Market Size - By Product (Cyclosporine, Topical Corticosteroids, Artificial Tears, Punctal Plugs, Oral Omega Supplements), By Disease Type (Evaporative Dry Eye Syndrome, Aqueous Deficient Dry Eye Syndrome), By Distribution Channel, & Forecast, 2023 – 2032

Dry Eye Disease Market Size

Dry eye disease market size was valued at over USD 6 billion in 2022 and is projected to reach around USD 12.3 billion by 2032. This incremental growth rate is owing to increasing prevalence of dry eye disease and associated ailments coupled with technological advancements in the products used for the treatment of these disorders.
 

Incrementally ageing population have augmented the demand for dry eye disease treatment devices thereby increasing awareness among several people across the globe. Geriatric population base are more susceptible to ophthalmic ailments as  eye discomfort, redness, blurred vision, and dryness are some of the major symptoms observed among ageing population. Technological advancements in therapeutic and diagnostic products and ongoing research and development activities to develop innovative treatments by industry players is anticipated to drive the market growth. Factors such as healthcare spending, patient demographics, and technological advancements exert a significant influence on the market.
 

Rising awareness regarding dry eye conditions and improved access to healthcare services have led to a surge in the demand for dry eye treatment devices. With the expanding market, there is a growing focus on developing personalized and targeted treatments, along with improved diagnostics and management approaches. Continued research and innovation are expected to enhance the understanding and treatment of dry eye disease, ultimately improving the quality of life for individuals affected by this condition thereby driving the market growth.
 

Dry eye disease (DED), also known as dry eye syndrome, is a common ocular condition characterized by insufficient tear production. This disease is specified by insufficient tear poor tear quality, leading to symptoms such as eye discomfort, redness, blurred vision, and dryness.
 

However, high cost associated with treatment drugs and products can pose a significant challenge and impede the market growth in the coming years. The expensive nature of these drugs and products can create barriers to access for patients, potentially limiting their ability to afford and adhere to the prescribed treatments. For instance, the cost of punctal plugs can range between USD 500 to USD 950 and may vary according to the type of punctal plugs and the undergoing treatment of the patient. Additionally, the cost of anti-inflammatory drugs such as cyclosporine is around USD 300 for 30 emulsions. The affordability issue can affect the market growth by reducing the overall demand for dry eye disease treatment options.
 

Moreover, the high cost of treatment drugs and products can also impact healthcare systems and insurance providers, leading to reimbursement challenges and financial burdens. This may result in limited coverage or restrictions on access to certain medications or therapies, further hindering market growth. The high cost of dry eye disease treatment drugs and products presents a potential impediment, ongoing efforts to improve affordability and access could help overcome these challenges and foster market progress.
 

COVID-19 Impact

The recent outbreak of COVID-19 had negatively influenced the dry eye disease market revenue, specifically during the initial phase of 2020. The coronavirus outbreak proliferated the disease burden and hampered several global businesses including the healthcare sector, during the pandemic phase. These conditions severely impacted the market growth. Several hospitals and healthcare facilities globally experienced a significant decline in patient visits for diagnosis and treatment of dry eye disorders and other related chronic conditions.
 

The COVID-19 pandemic has reduced visits to healthcare facilities, causing medical services in several countries to be delayed, including ophthalmic procedures. During the pandemic, many individuals postponed or avoided non-urgent healthcare visits, including eye care appointments. This led to delayed diagnosis and treatment of dry eye disease, resulting in missed opportunities for intervention and management.
 

Dry Eye Disease Market Trends

Increasing prevalence of eye-related diseases is anticipated to drive the market share. The global population is experiencing a significant increase in the aging demographic. With age, the risk of developing eye-related diseases, including dry eye disease, increases significantly. The prevalence of dry eye disease tends to be higher in older individuals. For instance, according to an article published by the Karger Journal, in 2022 the prevalence rate of dry eye disease among people aged above 50 years in Asia was estimated to be around 50% and is expected in increase in the coming years.
 

This high prevalence rate is set to augment the demand for dry eye disease treatment products globally. Prolonged screen time and decreased blink rate associated with digital device use can contribute to dry eye symptoms. The increasing dependence on digital devices has resulted in a higher prevalence of dry eye disease among all age groups.
 

Dry eye disease often coexists with other systemic conditions, such as autoimmune diseases, diabetes, and thyroid disorders. The rising prevalence of these comorbidities contributes to the increasing prevalence of dry eye disease. There has been a growing awareness and understanding of dry eye disease among both healthcare professionals and the general population. Increased knowledge about the condition has led to improved diagnosis rates. Eye care professionals are better equipped to identify and diagnose dry eye disease, leading to a higher reported prevalence.

Dry Eye Disease Market Analysis

Based on product, the dry eye disease market is segmented as cyclosporine, topical corticosteroids, artificial tears, punctal plugs, oral omega supplements and others. The cyclosporine segment dominated the market accounting over 35% business share in 2022. Cyclosporine is an immunomodulatory medication that has been found to provide several benefits in the diagnosis and treatment of dry eye disease. Dry eye disease is often associated with chronic inflammation of the ocular surface. Cyclosporine acts as an anti-inflammatory agent by inhibiting the activity of T-lymphocytes and suppressing the release of pro-inflammatory cytokines. This helps to reduce the inflammation and improve the overall ocular surface health in dry eye disease. Cyclosporine helps to enhance tear film stability by increasing the production of aqueous tears from the lacrimal gland. This results in improved lubrication of the ocular surface and alleviation of dry eye symptoms.
 

Cyclosporine has been shown to provide significant symptom relief in patients with dry eye disease. It helps to reduce the discomfort, dryness, grittiness, and foreign body sensation commonly experienced by individuals with this condition. By addressing the underlying inflammation and promoting tear production, cyclosporine can improve the overall quality of life for patients. Cyclosporine is often used as a long-term management option for chronic dry eye disease.
 

Based on disease type, the dry eye disease market is segmented as evaporative dry eye syndrome and aqueous deficient dry eye syndrome. The evaporative dry eye syndrome segment accounted for around USD 4.7 billion in 2022. Evaporative dry eye syndrome is a type of dry eye disease characterized by a deficiency in the oily component of tears, which leads to increased tear evaporation and ocular surface dryness. Some of the major factors influencing the development of evaporative dry eye, including meibomian gland dysfunction (MGD), blepharitis, rosacea, and lid abnormalities. For instance, according to the Dry Eye Directory data, in 2022, around 1 billion people globally were suffering from meibomian gland dysfunction. These rising diseases population is anticipated to drive the demand for dry eye disease treatment across the globe.
 

Modern lifestyles, characterized by increased digital device use, prolonged screen time, and reduced blink rate, contribute to the development of evaporative dry eye syndrome. As these lifestyle factors continue to be prevalent, the incidence of evaporative dry eye syndrome is expected to rise. Evaporative dry eye syndrome becomes more common with age, primarily due to the age-related changes in the meibomian glands and the eyelid structure. As the global population continues to age, the prevalence of evaporative dry eye syndrome is projected to increase.
 

Based on distribution channel, the dry eye disease market is segmented as hospital pharmacy, retail pharmacy and online pharmacy. The hospital pharmacy segment is expected to grow at 7.0% CAGR by 2032 owing to increasing demand for devices and drugs for the diagnosis and treatment of dry eye disease. Hospital pharmacies often cater to patients with more severe or complex cases of dry eye disease who require specialized treatment. These patients may benefit from prescription medications, such as anti-inflammatory agents or immunomodulators, which are typically available in hospital pharmacies. Hospital pharmacies are equipped to provide comprehensive care to patients with dry eye disease. They offer a range of treatment options, including prescription medications, over-the-counter products, and advanced devices used for diagnosis, management, and treatment.
 

Hospital pharmacies are often conveniently located within healthcare facilities, providing easy access for patients seeking dry eye disease treatment. Additionally, availability of highly skilled healthcare professionals coupled with robust healthcare infrastructure and appropriate patient assistance for a comprehensive range of treatment options underscores the importance of hospital pharmacies thereby augmenting the market trends.
 

North America dry eye disease market was valued at USD 2.4 billion in 2022. This high market share may be ascribed to a variety of factors, including the presence of significant industry players, an increase in the number of patients suffering from dry eye disease, an expanding elderly population, among others. North America has a relatively high prevalence of dry eye disease, driven by various factors such as an aging population, widespread use of digital devices, and environmental factors. For instance, according to the American Academy of Ophthalmology data, around 20 million people in the U.S. were suffering from dry eye disease and is estimated to grow in the coming years. High demand for anti-inflammatory drugs for the diagnosis and treatment of dry eye disease in the region is anticipated to drive the market expansion.
 

Dry Eye Disease Market Share

Some of the major players operating in the dry eye disease market are

• AbbVie, Inc
• AFT Pharmaceuticals
• Alcon
• Bausch & Lomb
• Johnson & Johnson Services, Inc
• Novartis AG
• OASIS Medical
• Otsuka Pharmaceutical Co., Ltd
• Oyster Point Pharma Inc
• Santen Pharmaceutical Co., Ltd
• Sentiss Pharma Pvt. Ltd
• Sun Pharmaceutical Industries Ltd
• Thea Pharmaceuticals Ltd
• VISUfarma
• Takeda Pharmaceutical Company Ltd

These leading market players are implementing advanced technologies to cater to the large unmet needs of the consumers. These players focus on strategic partnerships, new product launch & commercialization for market expansion. Furthermore, these players are heavily investing in research that allows them to introduce innovative products and garner maximum revenue in the market.
 

Dry Eye Disease Industry Leaders

• In January 2022, Alcon announced the launch of Systane, a complete preservative-free lubricant eye drop in the Europe. This eye drop is intended for the treatment of dry eye disease and provides dry eye relief by hydrating and protecting all layers of the tear film. This innovative launch heled the company to enhance their geographic presence and increase the customer base.
   
• In October 2020, Kala Pharmaceuticals, Inc., announced that they had received the U.S. FDA approval for their EYSUVIS an ophthalmic suspension. EYSUVIS, a loteprednol etabonate ophthalmic suspension 0.25% is used for the short-term treatment of the signs and symptoms of dry eye disease. This regulatory approval helped the company to enhance their R&D capabilities and increase their product portfolio.
   

Dry Eye Disease market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue (USD Million) from 2018 to 2032, for the following segments

Click here to Buy Section of this Report

By Product, 2018 - 2032 (USD Million)

• Cyclosporine
• Topical Corticosteroids
• Artificial Tears
• Punctal Plugs
  • Removable
  • Dissolvable
• Oral Omega Supplements
• Others

By Disease Type, 2018 - 2032 (USD Million)

• Evaporative Dry Eye Syndrome
• Aqueous Deficient Dry Eye Syndrome 

By Distribution Channel, 2018 - 2032 (USD Million)

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Poland
  • Sweden
  • The Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Indonesia
  • Thailand
  • Philippines
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Chile
  • Peru
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Egypt
  • Turkey